Overview

Assessment of the Effect of Empagliflozin (BI 10773) as Single Dose on the QT Interval in Healthy Female and Male Subjects

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The objective of this study is to demonstrate that BI 10773 does not prolong the QT(c) interval more than placebo
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Empagliflozin
Fluoroquinolones
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination